ShouTi, a clinical-stage biopharmaceutical company, announced the close of a $100 million Series B financing led by BVF Partners L.P. (BVF).

Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners LP, and co-founder and strategic partner Schrodinger.

With the completion of the Series B financing, ShouTi has raised $158 million since initiating operations.

Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.